Summary of Glaukos (GKOS) FY Conference June 03, 2025 Company Overview - Glaukos is focused on innovative treatments for glaucoma and other eye diseases, emphasizing dropless therapies and interventional glaucoma solutions [3][4][5] - The company has developed five novel platforms, including the iStent franchise and the latest product line, iDose [5][6] Key Products and Innovations - **iStent Franchise**: Established product line for treating glaucoma [5] - **iDose**: A new product that allows for continuous drug delivery, showing a 70% control rate of intraocular pressure over three years in trials [22][23] - **EyeLink**: A product targeting keratoconus, with an NDA submitted and a PDUFA date set for October 2025 [36] - **Ilucian**: A cream-based drug delivery system targeting Demodex blepharitis, with clinical trials starting this year [37] - **Retina Products**: Utilizing a small molecule approach for retinal diseases, with a phase one trial underway [39] Market Opportunity - The total addressable market for glaucoma treatment includes approximately 22 million eyes in the U.S., with 12 million actively treated [25] - The company aims to shift from a cataract surgery-focused market to a standalone glaucoma treatment market, which presents significant growth potential [25][26] Research and Development Investment - Over the past seven years, Glaukos has invested more than $700 million in R&D, resulting in 14 disclosed programs in the pipeline [7] - The company is committed to long-term innovation, with a focus on interventional glaucoma as a ten-year journey [28] Commercial Strategy - Emphasis on early intervention in glaucoma treatment to improve patient outcomes and reduce reliance on drops, which have low compliance rates [10][12] - The "forever patient" model allows for multiple treatment iterations over a patient's lifetime, enhancing both patient care and business opportunities for ophthalmologists [21][22] Financial Performance - Glaukos has achieved a ten-year compound annual growth rate (CAGR) of over 20% and maintains gross margins exceeding 80% [42] - The company has a strong balance sheet with over $300 million in cash and no debt [43] Future Milestones - Key milestones for 2025 include advancing clinical trials for new products and expanding market access for existing therapies [42] Conclusion - Glaukos is positioned as a leader in the ophthalmology market with a robust pipeline of innovative products aimed at improving patient care in glaucoma and other eye diseases, supported by strong financial health and a commitment to R&D [41][42]